Association of Patient Sex with Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers: A Systematic Review and Meta-analysis

Christopher J.D. Wallis, Mohit Butaney, Raj Satkunasivam, Stephen J. Freedland, Sandip P. Patel, Omid Hamid, Sumanta K. Pal, Zachary W A Klaassen

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Importance: Sex-associated differences in immune response are known, but a meta-analysis suggested men, compared with women, derive greater value from immunotherapy for advanced solid-organ malignant neoplasms. However, methodologic concerns and subsequent trials have placed these results in doubt. Objective: To perform an updated, comprehensive meta-analysis that assesses the efficacy of immunotherapy in advanced cancers according to patient sex. Design, Setting, and Participants: A systematic review of studies (n = 23) indexed in MEDLINE (PubMed), Embase, and Scopus from inception of these databases to October 2, 2018, was conducted. Randomized clinical trials that compared immunotherapy with standard of care in the treatment of advanced solid-organ malignant neoplasms were included if overall survival was reported as an outcome and if data stratified by patient sex were available. Observational studies, editorials, commentaries, review articles, non-peer-reviewed publications, studies that compared various immunotherapy regimens, studies that reported other measures of oncologic response, and studies that reported subgroup analyses for 1 sex only were excluded. Main Outcomes and Measures: Overall survival, with a test for heterogeneity between women and men, to assess the null hypothesis that no difference in the survival advantage of immunotherapy exists by patient sex. Results: This meta-analysis included 23 randomized clinical trials that reported on 9322 men (67.9%) and 4399 women (32.1%); the age of most patients was in the 70s. An overall survival benefit of immunotherapy was found for both men (hazard ratio [HR], 0.75; 95% CI, 0.69-0.81; P <.001) and women (HR, 0.77; 95% CI, 0.67-0.88; P =.002). Random-effects meta-analysis of study-level differences in response to immunotherapy demonstrated no statistically significant difference between the sexes (I2 = 38%; P =.60). Subgroup analyses according to disease site, line of therapy, class of immunotherapy, study methodology, and representation of women recapitulated these findings. Conclusions and Relevance: Stratified analyses demonstrated no statistically significant association of patient sex with the efficacy of immunotherapy in the treatment of advanced cancers using overall survival as the outcome.

Original languageEnglish (US)
Pages (from-to)529-536
Number of pages8
JournalJAMA Oncology
Volume5
Issue number4
DOIs
StatePublished - Apr 1 2019

Fingerprint

Immunotherapy
Meta-Analysis
Survival
Neoplasms
Sex Characteristics
Randomized Controlled Trials
Standard of Care
PubMed
MEDLINE
Observational Studies
Publications
Therapeutics
Outcome Assessment (Health Care)
Databases

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Association of Patient Sex with Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers : A Systematic Review and Meta-analysis. / Wallis, Christopher J.D.; Butaney, Mohit; Satkunasivam, Raj; Freedland, Stephen J.; Patel, Sandip P.; Hamid, Omid; Pal, Sumanta K.; Klaassen, Zachary W A.

In: JAMA Oncology, Vol. 5, No. 4, 01.04.2019, p. 529-536.

Research output: Contribution to journalArticle

Wallis, Christopher J.D. ; Butaney, Mohit ; Satkunasivam, Raj ; Freedland, Stephen J. ; Patel, Sandip P. ; Hamid, Omid ; Pal, Sumanta K. ; Klaassen, Zachary W A. / Association of Patient Sex with Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers : A Systematic Review and Meta-analysis. In: JAMA Oncology. 2019 ; Vol. 5, No. 4. pp. 529-536.
@article{8e7b3c7ecc344e1fafdc620f8bec107f,
title = "Association of Patient Sex with Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers: A Systematic Review and Meta-analysis",
abstract = "Importance: Sex-associated differences in immune response are known, but a meta-analysis suggested men, compared with women, derive greater value from immunotherapy for advanced solid-organ malignant neoplasms. However, methodologic concerns and subsequent trials have placed these results in doubt. Objective: To perform an updated, comprehensive meta-analysis that assesses the efficacy of immunotherapy in advanced cancers according to patient sex. Design, Setting, and Participants: A systematic review of studies (n = 23) indexed in MEDLINE (PubMed), Embase, and Scopus from inception of these databases to October 2, 2018, was conducted. Randomized clinical trials that compared immunotherapy with standard of care in the treatment of advanced solid-organ malignant neoplasms were included if overall survival was reported as an outcome and if data stratified by patient sex were available. Observational studies, editorials, commentaries, review articles, non-peer-reviewed publications, studies that compared various immunotherapy regimens, studies that reported other measures of oncologic response, and studies that reported subgroup analyses for 1 sex only were excluded. Main Outcomes and Measures: Overall survival, with a test for heterogeneity between women and men, to assess the null hypothesis that no difference in the survival advantage of immunotherapy exists by patient sex. Results: This meta-analysis included 23 randomized clinical trials that reported on 9322 men (67.9{\%}) and 4399 women (32.1{\%}); the age of most patients was in the 70s. An overall survival benefit of immunotherapy was found for both men (hazard ratio [HR], 0.75; 95{\%} CI, 0.69-0.81; P <.001) and women (HR, 0.77; 95{\%} CI, 0.67-0.88; P =.002). Random-effects meta-analysis of study-level differences in response to immunotherapy demonstrated no statistically significant difference between the sexes (I2 = 38{\%}; P =.60). Subgroup analyses according to disease site, line of therapy, class of immunotherapy, study methodology, and representation of women recapitulated these findings. Conclusions and Relevance: Stratified analyses demonstrated no statistically significant association of patient sex with the efficacy of immunotherapy in the treatment of advanced cancers using overall survival as the outcome.",
author = "Wallis, {Christopher J.D.} and Mohit Butaney and Raj Satkunasivam and Freedland, {Stephen J.} and Patel, {Sandip P.} and Omid Hamid and Pal, {Sumanta K.} and Klaassen, {Zachary W A}",
year = "2019",
month = "4",
day = "1",
doi = "10.1001/jamaoncol.2018.5904",
language = "English (US)",
volume = "5",
pages = "529--536",
journal = "JAMA oncology",
issn = "2374-2437",
publisher = "American Medical Association",
number = "4",

}

TY - JOUR

T1 - Association of Patient Sex with Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers

T2 - A Systematic Review and Meta-analysis

AU - Wallis, Christopher J.D.

AU - Butaney, Mohit

AU - Satkunasivam, Raj

AU - Freedland, Stephen J.

AU - Patel, Sandip P.

AU - Hamid, Omid

AU - Pal, Sumanta K.

AU - Klaassen, Zachary W A

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Importance: Sex-associated differences in immune response are known, but a meta-analysis suggested men, compared with women, derive greater value from immunotherapy for advanced solid-organ malignant neoplasms. However, methodologic concerns and subsequent trials have placed these results in doubt. Objective: To perform an updated, comprehensive meta-analysis that assesses the efficacy of immunotherapy in advanced cancers according to patient sex. Design, Setting, and Participants: A systematic review of studies (n = 23) indexed in MEDLINE (PubMed), Embase, and Scopus from inception of these databases to October 2, 2018, was conducted. Randomized clinical trials that compared immunotherapy with standard of care in the treatment of advanced solid-organ malignant neoplasms were included if overall survival was reported as an outcome and if data stratified by patient sex were available. Observational studies, editorials, commentaries, review articles, non-peer-reviewed publications, studies that compared various immunotherapy regimens, studies that reported other measures of oncologic response, and studies that reported subgroup analyses for 1 sex only were excluded. Main Outcomes and Measures: Overall survival, with a test for heterogeneity between women and men, to assess the null hypothesis that no difference in the survival advantage of immunotherapy exists by patient sex. Results: This meta-analysis included 23 randomized clinical trials that reported on 9322 men (67.9%) and 4399 women (32.1%); the age of most patients was in the 70s. An overall survival benefit of immunotherapy was found for both men (hazard ratio [HR], 0.75; 95% CI, 0.69-0.81; P <.001) and women (HR, 0.77; 95% CI, 0.67-0.88; P =.002). Random-effects meta-analysis of study-level differences in response to immunotherapy demonstrated no statistically significant difference between the sexes (I2 = 38%; P =.60). Subgroup analyses according to disease site, line of therapy, class of immunotherapy, study methodology, and representation of women recapitulated these findings. Conclusions and Relevance: Stratified analyses demonstrated no statistically significant association of patient sex with the efficacy of immunotherapy in the treatment of advanced cancers using overall survival as the outcome.

AB - Importance: Sex-associated differences in immune response are known, but a meta-analysis suggested men, compared with women, derive greater value from immunotherapy for advanced solid-organ malignant neoplasms. However, methodologic concerns and subsequent trials have placed these results in doubt. Objective: To perform an updated, comprehensive meta-analysis that assesses the efficacy of immunotherapy in advanced cancers according to patient sex. Design, Setting, and Participants: A systematic review of studies (n = 23) indexed in MEDLINE (PubMed), Embase, and Scopus from inception of these databases to October 2, 2018, was conducted. Randomized clinical trials that compared immunotherapy with standard of care in the treatment of advanced solid-organ malignant neoplasms were included if overall survival was reported as an outcome and if data stratified by patient sex were available. Observational studies, editorials, commentaries, review articles, non-peer-reviewed publications, studies that compared various immunotherapy regimens, studies that reported other measures of oncologic response, and studies that reported subgroup analyses for 1 sex only were excluded. Main Outcomes and Measures: Overall survival, with a test for heterogeneity between women and men, to assess the null hypothesis that no difference in the survival advantage of immunotherapy exists by patient sex. Results: This meta-analysis included 23 randomized clinical trials that reported on 9322 men (67.9%) and 4399 women (32.1%); the age of most patients was in the 70s. An overall survival benefit of immunotherapy was found for both men (hazard ratio [HR], 0.75; 95% CI, 0.69-0.81; P <.001) and women (HR, 0.77; 95% CI, 0.67-0.88; P =.002). Random-effects meta-analysis of study-level differences in response to immunotherapy demonstrated no statistically significant difference between the sexes (I2 = 38%; P =.60). Subgroup analyses according to disease site, line of therapy, class of immunotherapy, study methodology, and representation of women recapitulated these findings. Conclusions and Relevance: Stratified analyses demonstrated no statistically significant association of patient sex with the efficacy of immunotherapy in the treatment of advanced cancers using overall survival as the outcome.

UR - http://www.scopus.com/inward/record.url?scp=85059608729&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059608729&partnerID=8YFLogxK

U2 - 10.1001/jamaoncol.2018.5904

DO - 10.1001/jamaoncol.2018.5904

M3 - Article

AN - SCOPUS:85059608729

VL - 5

SP - 529

EP - 536

JO - JAMA oncology

JF - JAMA oncology

SN - 2374-2437

IS - 4

ER -